Opinion · 25 Jun 2026
Conference abstractPublished 17 Sep 2012
Role of nuclear pore complex in ovarian cancer chemoresistance
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Although ovarian carcinoma ranks fifth among cancer-related deaths in American women, it is the leading cause of death from gynecologic malignancy in the U.S. The treatment mainstay for ovarian cancer historically has been and remains surgical debulking, followed by chemotherapy. Preferred first-line agents are cisplatin and carboplatin. The emergence of cancer cell multi-drug resistance has spurred research efforts toward developing countermeasures. Among the many methods of drug resistance employed by cancer cells, are malfunctioning plasma membrane transporter proteins. We took a novel approach of bypassing the plasma membrane, and investigated nuclear membrane pore complexes (NPCs). The NPC is a several hundred multiprotein complex spanning the nuclear envelope, which is flexibly expandable and functions in the transport of water soluble substances, including RNA, ribosomes, proteins, carbohydrates, signaling molecules and lipids across the nuclear membrane, via an energy-linked transport cycle. A nucleus may contain hundreds to thousands of NPCs, and each may perform up to one thousand translocations per second, hence its importance in intracellular communication. We found that the induction of alteration in the NPC via knockdown of one protein constituent, NUP62 conferred cisplatin resistance upon cultured high-grade ovarian carcinoma (TOV112D) cells. Further, preliminary studies have shown that NUP62 is phosphorylated in the coiled-coil domain by the protein tyrosine kinase PYK2. Activation of PYK2 is associated with chemoresistance in some tumor types, and as the coiled-coil domain mediates interactions between NUP62 and the NPC, phosphorylation of this domain may functionally alter nuclear pore architecture in a manner mimicked by NUP62 knockdown.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Translational Medicine.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Tamara Kalir”
